Rachel Reeves

Reeves explicitly states they have "secured a deal around pharmaceuticals" with the US which is "crucial for the UK" and asserts these terms are "not affected by the Supreme Court ruling" or current diplomatic tensions. While the broader UK-US trade relationship faces headwinds due to the UK's refusal to join offensive military action against Iran, the pharmaceutical sector has been ring-fenced. This regulatory certainty provides a safe harbor for UK pharma giants compared to other export sectors that may face retaliatory tariffs or "uncertainty." Long UK Pharma majors as a defensive play against geopolitical volatility; they retain access to their most critical market (US) regardless of the political spat. Unexpected executive orders from the US administration specifically targeting UK imports despite prior agreements.

Reeves claims the UK has secured "probably the best trade deal that any country in the world has secured with India" and expects to "bring that into effect in the next couple of months." A comprehensive trade deal reduces tariffs and non-tariff barriers, boosting volume for Indian exporters targeting the UK market. As the UK pivots away from US reliance, India stands to capture market share in goods and services. Long India ETFs to capture the macro lift from increased trade volume and preferential access to the UK economy. Implementation delays or bureaucratic hurdles in the final ratification of the deal.

Reeves announces a major policy shift to improve relations with the European Union, specifically targeting "energy and electricity trading," "food and farming," and "youth mobility." This represents a structural reduction in "Brexit friction." By reintegrating energy and food supply chains with the EU, the UK lowers input costs and inflation volatility. A "reset" with the EU acts as a counterweight to US isolationism ("pull up the drawbridge"), improving the fundamental outlook for the British economy. Long UK broad equities as the government moves to lower structural trade barriers with its largest neighbor, improving productivity and growth prospects. Domestic political backlash in the UK regarding "rejoining" EU schemes; resistance from EU negotiators.

Reeves explicitly states they have "secured a deal around pharmaceuticals" with the US which is "crucial for the UK" and asserts these terms are "not affected by the Supreme Court ruling" or current diplomatic tensions. While the broader UK-US trade relationship faces headwinds due to the UK's refusal to join offensive military action against Iran, the pharmaceutical sector has been ring-fenced. This regulatory certainty provides a safe harbor for UK pharma giants compared to other export sectors that may face retaliatory tariffs or "uncertainty." Long UK Pharma majors as a defensive play against geopolitical volatility; they retain access to their most critical market (US) regardless of the political spat. Unexpected executive orders from the US administration specifically targeting UK imports despite prior agreements.

Reeves claims the UK has secured "probably the best trade deal that any country in the world has secured with India" and expects to "bring that into effect in the next couple of months." A comprehensive trade deal reduces tariffs and non-tariff barriers, boosting volume for Indian exporters targeting the UK market. As the UK pivots away from US reliance, India stands to capture market share in goods and services. Long India ETFs to capture the macro lift from increased trade volume and preferential access to the UK economy. Implementation delays or bureaucratic hurdles in the final ratification of the deal.